To use MIBI or not to use MIBI? That is the question when assessing tumour cells

Basit Öğe Kaydı
dc.contributor.authorMoretti, JL
dc.contributor.authorHauet, N
dc.contributor.authorCaglar, M
dc.contributor.authorRebillard, O
dc.contributor.authorBurak, Z
dc.date.accessioned2019-10-27T19:24:32Z
dc.date.available2019-10-27T19:24:32Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractTc-99m-sestamibi (MIBI) is a well-known tumour imaging agent. Its retention within tumour cell mitochondria is related to perfusion and to the magnitude of the electrical gradient, reflecting cell viability. Several internal cell factors modulate this uptake; for example, multidrug resistance membrane proteins (Pgp and MRP1) and anti-apoptotic BCl-2 protein of the outer mitochondrial membrane can limit retention of MIBI. At the early stage of cell apoptosis, the electrical driving forces of MIBI uptake are impaired, and influx and accumulation are reduced. It seems clear that MIBI can be used before treatment to detect drug resistance, assess anti-apoptotic status and predict treatment efficacy. Although it has been suggested that MIBI might be used to monitor tumour response to treatment, MIBI is unable to differentiate tumours with ongoing apoptosis from those developing drug resistance.en_US
dc.identifier.doi10.1007/s00259-005-1840-xen_US
dc.identifier.endpage842en_US
dc.identifier.issn1619-7070
dc.identifier.issn1619-7089
dc.identifier.issue7en_US
dc.identifier.pmid15902437en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage836en_US
dc.identifier.urihttps://doi.org/10.1007/s00259-005-1840-x
dc.identifier.urihttps://hdl.handle.net/11454/39279
dc.identifier.volume32en_US
dc.identifier.wosWOS:000230903600016en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Journal of Nuclear Medicine and Molecular Imagingen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTc-99m-sestamibien_US
dc.subjectMIBIen_US
dc.subjectmultidrug resistanceen_US
dc.subjectapoptosisen_US
dc.subjecttreatment responseen_US
dc.titleTo use MIBI or not to use MIBI? That is the question when assessing tumour cellsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu